CClinicalTrials.gg
RecruitingNCT07351422TAK-IMPACTUpdated Jan 20, 2026

Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis

An observational study in Takayasu Arteritis and Takayasu Arteritis (TAK), sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by University of Edinburgh · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians.

Read the detailed description

This study aims to investigate the experiences and perceptions of patients with Takayasu arteritis regarding their disease, as well as the perspectives of physicians regarding the management and treatment of these patients.

Patients with TAK will be invited to complete an anonymous online (Online Surveys) questionnaire, which will take approximately 25 minutes and will consist of multiple-choice and short-answer questions. The questionnaire will ask about their experience with the condition, symptoms, treatments they have received, and any concerns or priorities they have regarding their care.

Physicians who treat TAK will also be invited to complete a separate online questionnaire, taking around 15 minutes and also consisting of multiple-choice and short-answer questions. This will explore how they diagnose and manage TAK, their choice of treatments, and any challenges they face in treating the condition

02

Conditions studied

  • Takayasu Arteritis
  • Takayasu Arteritis (TAK)

Browse trials for

03

In context

Takayasu Arteritis

76 studies on the registry are indexed under Takayasu Arteritis; 30 are open to participants now.

This study's planned enrollment of 50 is below the median of 300 across 39 observational studies indexed under Takayasu Arteritis.

Browse Takayasu Arteritis studies →

Lead sponsor

University of Edinburgh is the lead sponsor of 393 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants are UK-based

Inclusion criteria

For the patient questionnaire:

  • Age ≥ 18 years
  • A formal diagnosis of TAK

For the physician questionnaire

  • A physician involved in the management/decision-making for patients diagnosed with TAK

Exclusion criteria

Exclusion Criteria:

For the patient questionnaire:

  • Age \< 18 years
  • Lack of a formal diagnosis of TAK
  • Patients without mental capacity or willingness to provide informed consent
  • Not UK based

For the physician questionnaire

  • Not involved in the management/ decision making for patients diagnosed with TAK
  • Not willing to take part
  • Not UK based
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Takayasu Arteritis

    Other: Questionnaire

  • Physicians Involved in the Management of Patients with Takayasu Arteritis

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    An online annoymous questionnaire consisting of short-answer and multiple-choice questions

06

What researchers measure

Primary outcomes

  1. Patient Perspective

    To understand the lived experiences of individuals with TAK, including their symptoms, health status post-diagnosis, treatment priorities, and concerns. The questionnaire covers the following topics: * Basic background information * Living with Takayasu arteritis * Changes to health since diagnosis * Physical activity and exercise habits- measured by the International Physical Activity Questionnaire (IPAQ) * Smoking history * Mental well-being- measured by the EQ-5D instrument * Nutrition and diet * Personal views and priorities on management

    Time frame: Day 1

  2. Physician Perspective

    To evaluate current clinical management strategies for TAK, identify treatment priorities, and highlight areas of unmet need in clinical practice. The physician questionnaire covers the following topics: * Clinical background and experience with TAK patients * Diagnostic and treatment strategies for TAK * Consideration of cardiovascular disease risk in TAK management * Physician priorities and unmet needs of management

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • University of Edinburgh
    Edinburgh, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351422
Lead sponsor
University of Edinburgh
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Oct 1, 2025
Primary completion
Mar 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Jan 20, 2026

Study contacts

Alexandra Armstrong
Contact
A.Armstrong-9@sms.ed.ac.uk
+447445695898

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion